Silo Pharma acquires software assets for 165k shares; seller is affiliate advisor

Silo Pharma, Inc.

Asset purchase agreement dated Aug 18, 2026 with Parkview Consulting LLC; consideration is 165,000 common shares (par $0.0001).
Assets include software "Reputation Endpoints" with full source/object code and related IP; seller is Corwin Yu, lead strategic advisor on Silo's Crypto Advisory Board.
Shares subject to 12-month lock-up, ending earlier on change of control or company consent; sale exempt under Section 4(a)(2).
Seller indemnifies for misrepresentation, IP infringement, gross negligence/fraud; reps survive 12 months.
Agreement governed by New York law; transaction closed effective August 18, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.